Adherence to guidelines for glucose assessment in starting second-generation antipsychotics

Pediatrics

Volumn 134, Issue 5, 2014, Pages e1308-e1314

  Raebel, Marsha A ^a   Penfold, Robert ^b   McMahon, Ann W ^c   Reichman, Marsha ^d   Shetterly, Susan ^a   Goodrich, Glenn ^a   Andrade, Susan ^e   Correll, Christoph U ^f   Gerhard, Tobias ^g,h  

^a KAISER PERMANENTE   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c Office of the Commissioner   (United States)

^d Center for Drug Evaluation and Research   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f ZUCKER HILLSIDE HOSPITAL   (United States)

^g RUTGERS UNIVERSITY   (United States)

^h RUTGERS UNIVERSITY   (United States)

Author keywords

Adolescent; Antipsychotic agents; Aripiprazole; Child; Glucose; Glycosylated hemoglobin; Guideline adherence; Hyperglycemia; Monitoring; Olanzapine; Quetiapine; Retrospective studies; Risperidone; Second generation antipsychotic; Youth

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HEMOGLOBIN A1C; OLANZAPINE; QUETIAPINE; RISPERIDONE; GLUCOSE BLOOD LEVEL; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RISK ASSESSMENT; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS; DRUG EFFECTS; METABOLISM; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STANDARDS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84908876428     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0828     Document Type: Article

References (34)

1. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685
2. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770-w781
3. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247-1256
4. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126
5. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93
6. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19 (2):101-109
7. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773
8. Andrade SE, Lo JC, Roblin D, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128(6):1135-1141
9. Margari L, Matera E, Craig F, et al. Tolerability and safety profile of risperidone in a sample of children and adolescents. Int Clin Psychopharmacol. 2013;28(4):177-183
10. Gerhard T, Bobo WB, Olfson M, Crystal S. Second generation antipsychotics and risk of type 2 diabetes in publicly insured children and adolescents. Pharmacoepidemiol Drug Saf. 2012;21:135
11. Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70(10):1067-1075
12. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42
13. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601
14. De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011;199(2):99-105
15. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009;166(3):345-353
16. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125-147
17. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System - a national resource for evidence development. N Engl J Med. 2011;364(6):498-499 doi:10.1056/NEJMp1014427
18. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):1-8 doi:10.1002/pds.2343
19. Gerhard T, Raebel M, Reichman M, et al. Mini-Sentinel assessment protocol metabolic effects of second generation antipsychotics in youth. Available at: http://www. mini-sentinel.org/work-products/Assessments/Mini-Sentinel-Metabolic-Effects-Second-Generation-Antipsychotics-Youth-Protocol.pdf. Accessed February 19, 2014
20. Maro JC, Platt R, Holmes JH, et al. Design of a national distributed health data network. Ann Intern Med. 2009;151(5):341-344
21. Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multiinstitutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010;48(suppl 6):S45-S51 doi:10.1097/MLR.0b013e3181d9919f
22. Toh S, Platt R, Steiner JF, Brown JS. Comparative-effectiveness research in distributed health data networks. Clin Pharmacol Ther. 2011;90(6):883-887 doi:10.1038/clpt.2011.236
23. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):23-31 doi:10.1002/pds.2336
24. Raebel MA, Haynes K, Woodworth TS, et al. Electronic clinical laboratory test results data tables: lessons from Mini-Sentinel. Pharmacoepidemiol Drug Saf. 2014;23(6):609-618
25. Rosati K, Evans B, McGraw D. HIPAA and common rule compliance in the Mini-Sentinel pilot, white paper. Available at: http://minisentinel.org/work-products/About-Us/HIPAA-and-CommonRuleCompliance-in-the-Mini-SentinelPilot.pdf. Accessed August 19, 2013
26. Department of Health and Human Services, Office of the Secretary. Standards for privacy of individually identifiable health information; final rule. 45 CFR Parts 160 and 164. Federal Register. 2002;53182-53273. Available at: http://www.ihs.gov/privacyact/documents/privrulepd.pdf. Accessed August 19, 2014
27. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997-2004
28. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry. 2008;20(2):195-201
29. Maayan LA, Vakhrusheva J. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Hum Psychopharmacol. 2010;25(2):133-138
30. de Hoogd S, Overbeek WA, Heerdink ER, Correll CU, de Graeff ER, Staal WG. Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of secondgeneration antipsychotics. J Child Adolesc Psychopharmacol. 2012;22(2):166-173
31. Goëb JL, Marco S, Duhamel A, et al. Metabolic side effects of risperidone in children and adolescents with early-onset schizophrenia. Prim Care Companion J Clin Psychiatry. 2008;10(6):486-487
32. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J; CAMESA guideline group. Evidencebased recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20(3):218-233
33. Morrato EH, Nicol GE, Maahs D, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med. 2010;164(4):344-351
34. Morrato EH, Druss BG, Hartung DM, et al. Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users. Pharmacoepidemiol Drug Saf. 2011;20(1):66-75